AI-generated analysis. Always verify with the original filing.
Ascentage Pharma Group International reported full year 2025 unaudited financial results with product sales and commercial rights revenues of US$82.1 million, up 90% year-over-year, driven by Olverembatinib sales of US$62.2 million (up 81%) and Lisaftoclax sales of US$10.1 million since launch, alongside updates on nine ongoing registrational Phase III trials.
Event Type
Disclosure
Voluntary
Variant
6-K
Current Report on Form 6-K
| Metric | Value | Basis |
|---|---|---|
| Revenue | $82.10 | |
| Olverembatinib Product Sales | $62.20 | |
| Lisaftoclax Product Sales | $10.10 | |
| Selling and Distribution Expenses | $50.60 | |
| Research and Development Expenses | $162.70 | |
| Administrative Expenses | $35.20 | |
| Finance Costs | $7.70 | |
| Loss | $177.70 |